Skip to main content
Graphical abstract for Tsukamoto et al., Targeting cap1 RNA methyltransferases as an antiviral strategy, Cell Chemical Biology (2023)

Publication

Review on new antiviral strategy now online

The review publication of Yuta Tsukamoto et al. is now available in the current issue of Cell Chemical Biology. Based on his latest Science paper, Yuta Tsukamoto now highlights the importance and potential of “Targeting cap1 RNA methyltransferases as an antiviral strategy”. He and his co-authors outline the game-changing options in the treatment of viral infections.


Publication

Tsukamoto Y, Igarashi M, Kato H.
Targeting cap1 RNA methyltransferases as an antiviral strategy.
Cell Chem Biol. 2023 Dec 5:S2451-9456(23)00426-9.
doi: 10.1016/j.chembiol.2023.11.011.
Epub ahead of print. PMID: 38091983.

Related news

Kathrin Leppek Publication PM

Publication

Starting points for the control of protein synthesis

—Bonn researchers develop a versatile toolbox for the characterization of IRESes in cells.
View entry
Pandyra Publication Graphical Abstract

Publication

Genetic mutation affects survival after viral infection

—Scientists discovered that haploinsufficiency in the Pax5 gene affects antiviral responses. The study was led by Prof. Dr. Aleksandra Pandyra from the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn in collaboration with Prof. Dr. Arndt Borkhardt, Clinic Director at the Pediatric Oncology at the University Hospital Düsseldorf. The findings were published in the latest edition of EMBO Molecular Medicine.
View entry
AG Kürthen Multiple Sclerosis Bonn

Publication

Potential target for MS therapy discovered

—Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system caused by the immune system. B cells, which are a type of white blood cell, play a role in the development of MS and are thus a target for therapies. Researchers at the University Hospital Bonn (UKB), the University of Bonn and the FAU Erlangen-Nuremberg identified the membrane protein MLC1 as a potential target antigen in MS. The results of the work have now been published in the renowned journal “Neurology Neuroimmunology & Neuroinflammation”.
View entry

Back to the news overview